| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6b4dd7c320939f7adca44cad3715c843 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07J41-0016
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07J41-0044
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07J41-0005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07J43-003
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-565 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07J41-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-566
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-32 |
| filingDate |
2018-06-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e99343c83b2c6805c7501b58828533be
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7396a9cb6a33bf5d16bf96caaa850da7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a2be59f6876a39616d0b4795356c318b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_702885426d6f76f0ac0e3095fc56dd58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bd5c6e3fc887bfc0e71d35e070b104a1 |
| publicationDate |
2020-01-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
AU-2018279205-A1 |
| titleOfInvention |
15.beta.-(3-propanamido)-substituted estra-1,3,5(10)-trien-17-one compounds and their 17-oximes for use in inhibition of 17.beta.-hydroxysteroid dehydrogenases |
| abstract |
The invention relates to compounds of formula (I) and pharmaceutically acceptable salts thereof (I) wherein R1 to R4 are as defined in the claims. The invention further relates to their use as inhibitors of 17β-HSD1 and in treatment or prevention of steroid hormone de- pendent diseases or disorders, such as steroid hormone dependent diseases or disorders requiring the inhibition of the 17β-HSD1 enzyme and/or requiring the lowering of the endogenous estradiol concentration. The present invention also relates to the preparation of the aforementioned compounds and to pharmaceutical compositions comprising as an active ingredient(s) one or more of the afore mentioned compounds or pharmaceutically acceptable salts thereof. |
| priorityDate |
2017-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |